Mgc Pharmaceuticals Share Discussion Threads

[fxl5] 04/1/2023 14:56

Cannabis medical market eill have huge interest this year. Big chart brekout on cards. Financial review smart move ahead of big new contracts this year and possible takeover.

[livewireplus] 03/1/2023 07:48

Yeah, have heard about Mrs. Tina - none of her trading has gone right recently and she has taken to hanging around on street corners wearing a mini-skirt and lots of make-up. PS: RNS for MXC out this morning ...

[looneytune] 02/1/2023 21:53

Happy New Year!!

Internal Costs Review Completed and Board Change
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based pharmaceutical company specialising in the production and development of plant inspired medicines, advises that as a result of the ongoing strategic review of its business and operations, the board has implemented further cost reductions which enable the Company to direct a greater portion of its working capital to advancing its clinical trial and research programs in 2023.
As a result of this review the board have agreed to an immediate ~35% reduction in director fees, effective from 1 December 2022. In addition to the reduction in director fees, the key executive officer team (i.e. non-directors) of the Company have also agreed to a 10-20% reduction in their cash remuneration, with only the key executive officers to be issued MGC shares in lieu of the reduction in their cash salary.
The board believes that this approach is appropriate in the current economic climate, as it helps to reallocate working capital to the prioritised clinical and research programs in 2023, retain experienced executives to execute the Company’s business plans, and better align executives’ pay with shareholder returns.
Resignation of Director of Mr Evan Hayes
The board also advises that Mr Evan Hayes has resigned from his position as a non-executive director of the Company, effective 1st January 2023, as part of the Company’s transition to a dedicated life sciences pharmaceuticals company. As a result of Mr Hayes’ departure, MGC’s board will be reduced to 5 directors, with the Company continuing to evaluate the composition of the board over the next 6 months to ensure that it reflects its position as a European based life sciences pharmaceutical company.
The Board would like to thank Mr Hayes for his valued contribution during his tenure on the board, and wish him well for the future.
3 January 2023
ASX Code: MXC
LSE Code: MXC
--Ends--
Authorised for release by the board of directors for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director [phone] [e-mail]
UK Financial and Corporate Advisor
Hannam & Partners
Rupert Fane / Nilesh Patel
[phone]
[e-mail] / [e-mail]
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson [phone] [e-mail]
[e-mail] | mgcpharma.co.uk
MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872
T: [phone]
MGC Pharmaceuticals Ltd
David Lim
Company Secretary
[phone] [e-mail]
UK Broker
Turner Pope
Andy Thacker
[phone] [e-mail]

[a_2_b] 28/12/2022 11:36

Jeez the confetti just doesn't stop here does it

[heatseek77] 22/12/2022 18:56

Youfatman 🐈🐈 sado troll get a life difficult when your family walks out on ya 🤣😂 sad old and bald so much going for you.

Lonely Xmas for ya, chatting with yourself and your mate 'Paul' on the web 😂 giving yourself thumbs up 🤣

[heatseek77] 21/12/2022 10:11

So classy oh 🐈

[heatseek77] 20/12/2022 09:03

Are you Paul Murphy?? Certainly not someone who frequents my circle, then I'm not a scum mouthed oink from upt t north...

Your such a sad lonely troll having shorten / change names didn't work for your bad robot alias did it... It's called intention

Merry Christmas to all the normal folk on here Ant,Loon,Sam, Pierre etc

[heatseek77] 19/12/2022 08:00

Yep looney is right ignore - mad england one of amaretto many many sado aliases
Ibatman more like youfatman (with a shiny bald head 😂)

looneytune - 29 Sep 2021 - 07:15:18 - 274 of 4333 MXC Moderated - MXC
Seriously people just ignore Mad England, this person is very clearly here to provoke and if you can't see that from his recent 2 posts then you should not be here. By all means read it but seriously just take it as light banter!!
I sure hope MGC raise funds as that was one of the main reasons for listing on the LSE!
Bring it on. Great products and monumental prospects!

[a_2_b] 08/12/2022 17:38

Not checked in a while share price is absolutely criminal glad I cut my losses months months ago

[looneytune] 07/12/2022 06:13

7 December 2022
ASX Code: MXC
LSE Code: MXC
Completion of CimetrATM Efficacy Pre-clinical Trial
Key Highlights:
• A pre-clinical study has now been completed on a model of cytokine storm in rodents using the CimetrATM formulation, and has demonstrated an anti-inflammatory effect in three different dosages of treatments.
• The study results demonstrate CimetrATM’s effect on the anti-inflammatory and pro-inflammatory cytokines and chemokines which support the previous anti-inflammatory results of CimetrATM.
• The study results will form part of the US Food and Drug Administration (FDA) application to register CimetrATM as an Investigational New Drug (IND), and is a critical milestone in the process of drug registration.
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed pre-clinical trial testing the efficacy of the CimetrATM formulation on rodents exhibiting the cytokine storm, in order to measure the anti-inflammatory effects of three different dosages.
The trial, carried out at the GLP-certified Science in Action Laboratory in Ness Ziona, Israel, demonstrated the anti-inflammatory effect of the treatment, with the histopathology showing the reduction of lung inflammation resulting from the onset of a cytokine storm1, in comparison to the control group. This was measured through the relative protein concentration of the cellular and acellular concentrations of the lung system.
This study is the next step in the regulatory process for Investigational New Drug (IND) approval, and is one of a cohort of studies needed to evaluate safety and efficacy in preclinical and clinical models. An IND application is expected to be submitted Q1 2023 for CimetrATM, as set out in prior company releases.
Through these studies, CimetrATM has been shown to reduce the production of Interleukin 1α (IL-1α), an inflammatory cytokine responsible for activating the escalation of disease manifested in the form of severe acute or chronic inflammation. Study groups included Naïve, LPS, LPS solvent PBS, LPS+CimetrATM 48 μg, LPS+CimetrATM 96 μg, LPS+CimetrATM 192 μg. The graph displaying the results for each study group, control and treatment, is shown below:
1 Cytokine Storm: A severe immune overreaction in which the body releases higher than normal levels of inflammatory cytokines into
[e-mail] | mgcpharma.co.uk 1
the blood too quickly
MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872
T: [phone]
- 3

Secondary test work illustrated the effect of CimetrATM on the Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), which is a chemotactic chemokine secreted by macrophages – the white blood cells that stimulate the body’s immune system. The protein performs various biological functions, such as recruiting inflammatory cells, wound healing, inhibition of stem cells, and maintaining effector immune response.
IL-17 has anti-inflammatory activity and this cytokine can suppress the development of autoimmune and inflammatory disease.
The study was completed on 55 rodents and the results presented efficacy results are statistically significant (p<0.05). This model demonstrates the anti-inflammatory mechanism of action of CimetrATM and will support the future definition of the clinical program, based on the cytokines that were affected by the drug.
Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: “The completion of this study is critical in the advancement of our submission to the FDA and for the final approval of CimetrATM as an IND in the US. There are further efficacy and safety trials to support our application, but these results are key step in the demonstration of CimetrATM as a treatment for the symptoms of the cytokine storm.”
--Ends--
2 - 3

Authorised for release by the Managing Director, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director [phone] [e-mail]
UK Financial and Corporate Advisor
Hannam & Partners
Rupert Fane / Nilesh Patel
[phone]
[e-mail] / [e-mail]
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson [phone] [e-mail]
About MGC Pharma
MGC Pharmaceuticals Ltd
David Lim
Company Secretary [phone] [e-mail]
UK Broker
Turner Pope
Andy Thacker
[phone] [e-mail]
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceuticals company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels

[looneytune] 07/12/2022 06:05

7 December 2022
ASX Code: MXC
LSE Code: MXC
Completion of CimetrATM Efficacy Pre-clinical Trial
Key Highlights:
• A pre-clinical study has now been completed on a model of cytokine storm in rodents using the CimetrATM formulation, and has demonstrated an anti-inflammatory effect in three different dosages of treatments.
• The study results demonstrate CimetrATM’s effect on the anti-inflammatory and pro-inflammatory cytokines and chemokines which support the previous anti-inflammatory results of CimetrATM.
• The study results will form part of the US Food and Drug Administration (FDA) application to register CimetrATM as an Investigational New Drug (IND), and is a critical milestone in the process of drug registration.
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has completed pre-clinical trial testing the efficacy of the CimetrATM formulation on rodents exhibiting the cytokine storm, in order to measure the anti-inflammatory effects of three different dosages.
The trial, carried out at the GLP-certified Science in Action Laboratory in Ness Ziona, Israel, demonstrated the anti-inflammatory effect of the treatment, with the histopathology showing the reduction of lung inflammation resulting from the onset of a cytokine storm1, in comparison to the control group. This was measured through the relative protein concentration of the cellular and acellular concentrations of the lung system.
This study is the next step in the regulatory process for Investigational New Drug (IND) approval, and is one of a cohort of studies needed to evaluate safety and efficacy in preclinical and clinical models. An IND application is expected to be submitted Q1 2023 for CimetrATM, as set out in prior company releases.
Through these studies, CimetrATM has been shown to reduce the production of Interleukin 1α (IL-1α), an inflammatory cytokine responsible for activating the escalation of disease manifested in the form of severe acute or chronic inflammation. Study groups included Naïve, LPS, LPS solvent PBS, LPS+CimetrATM 48 μg, LPS+CimetrATM 96 μg, LPS+CimetrATM 192 μg. The graph displaying the results for each study group, control and treatment, is shown below:
1 Cytokine Storm: A severe immune overreaction in which the body releases higher than normal levels of inflammatory cytokines into
[e-mail] | mgcpharma.co.uk 1
the blood too quickly
MGC Pharmaceuticals Ltd | 1202 Hay Street, West Perth, WA 6005 PO Box 1976, West Perth WA 6872
T: [phone]
- 3

Secondary test work illustrated the effect of CimetrATM on the Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), which is a chemotactic chemokine secreted by macrophages – the white blood cells that stimulate the body’s immune system. The protein performs various biological functions, such as recruiting inflammatory cells, wound healing, inhibition of stem cells, and maintaining effector immune response.
IL-17 has anti-inflammatory activity and this cytokine can suppress the development of autoimmune and inflammatory disease.
The study was completed on 55 rodents and the results presented efficacy results are statistically significant (p<0.05). This model demonstrates the anti-inflammatory mechanism of action of CimetrATM and will support the future definition of the clinical program, based on the cytokines that were affected by the drug.
Roby Zomer, co-founder and Managing Director of MGC Pharmaceuticals, commented: “The completion of this study is critical in the advancement of our submission to the FDA and for the final approval of CimetrATM as an IND in the US. There are further efficacy and safety trials to support our application, but these results are key step in the demonstration of CimetrATM as a treatment for the symptoms of the cytokine storm.”
--Ends--
2 - 3

Authorised for release by the Managing Director, for further information please contact:
MGC Pharmaceuticals Ltd
Roby Zomer
CEO & Managing Director [phone] [e-mail]
UK Financial and Corporate Advisor
Hannam & Partners
Rupert Fane / Nilesh Patel
[phone]
[e-mail] / [e-mail]
UK PR Advisors
Tavistock
Charles Vivian / Tim Pearson [phone] [e-mail]
About MGC Pharma
MGC Pharmaceuticals Ltd
David Lim
Company Secretary [phone] [e-mail]
UK Broker
Turner Pope
Andy Thacker
[phone] [e-mail]
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceuticals company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.
The Company’s founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.
MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company’s EU-GMP Certified manufacturing facilities.
MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.
Follow us through our social media channels

[kenbos] 06/12/2022 08:07

What other orders have they ?